Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 424

1.

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M.

N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available.

PMID:
31189043
2.

Displaced Meniscus Tear in the Acute Postoperative Period After Total Hip Arthroplasty: A Case Report.

Johnson DB Jr, Triplet JJ, Streit AR, Long NK, Wasielewski RC.

JBJS Case Connect. 2019 Jun 11. doi: 10.2106/JBJS.CC.18.00124. [Epub ahead of print]

PMID:
31188794
3.

Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Jun 11. pii: molcanres.0257.2019. doi: 10.1158/1541-7786.MCR-19-0257. [Epub ahead of print]

PMID:
31186280
4.

Upconversion of Cellulosic Waste Into a Potential "Drop in Fuel" via Novel Catalyst Generated Using Desulfovibrio desulfuricans and a Consortium of Acidophilic Sulfidogens.

Mikheenko IP, Gomez-Bolivar J, Merroun ML, Macaskie LE, Sharma S, Walker M, Hand RA, Grail BM, Johnson DB, Orozco RL.

Front Microbiol. 2019 May 10;10:970. doi: 10.3389/fmicb.2019.00970. eCollection 2019.

5.

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE.

J Immunother Cancer. 2019 May 22;7(1):134. doi: 10.1186/s40425-019-0617-x.

6.

Immunotherapy in Older Adults with Cancer.

Godby RC, Johnson DB, Williams GR.

Curr Oncol Rep. 2019 May 7;21(7):56. doi: 10.1007/s11912-019-0806-2. Review.

PMID:
31065907
7.

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

Wang Y, Johnson DB, Lu S, Diaz LA Jr, Xu Y, Balko JM.

J Immunother Cancer. 2019 May 7;7(1):123. doi: 10.1186/s40425-019-0584-2.

8.

Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB.

JAMA Oncol. 2019 Apr 18. doi: 10.1001/jamaoncol.2019.0046. [Epub ahead of print] No abstract available.

PMID:
30998826
9.

Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.

Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE.

Eur J Cancer. 2019 May;113:10-13. doi: 10.1016/j.ejca.2019.03.002. Epub 2019 Apr 4. No abstract available.

PMID:
30954881
10.

Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Quach HT, Robbins CJ, Balko JM, Chiu CY, Miller S, Wilson MR, Nelson GE, Johnson DB.

Oncologist. 2019 Apr 1. pii: theoncologist.2018-0722. doi: 10.1634/theoncologist.2018-0722. [Epub ahead of print]

PMID:
30936376
11.

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2019 Mar 26;321(12):1219-1220. doi: 10.1001/jama.2018.22123. No abstract available.

PMID:
30912830
12.

Mid-term outcomes following primary semi-constrained total knee arthroplasty in patients less than 60 years old, a retrospective review.

Johnson DB Jr, Triplet JJ, Gaines DR, Gupta A, Unverferth KL.

Knee. 2019 Jun;26(3):714-719. doi: 10.1016/j.knee.2019.02.001. Epub 2019 Mar 19.

PMID:
30902516
13.

Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.

Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB.

J Immunother. 2019 Jul/Aug;42(6):221-227. doi: 10.1097/CJI.0000000000000258.

PMID:
30882548
14.

Validation of a Two-Item Food Security Screening Tool in a Dental Setting.

Radandt NE, Corbridge T, Johnson DB, Kim AS, Scott JM, Coldwell SE.

J Dent Child (Chic). 2018 Sep 15;85(3):114-119.

15.

Hematologic Complications of Immune Checkpoint Inhibitors.

Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB.

Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.

PMID:
30819785
16.

Retrograde Femoral Bone Graft Acquisition Using the Reamer-Irrigator-Aspirator.

Taylor BC, Triplet JJ, Johnson DB, Sharpe BD, Sullivan B, Canini C.

J Long Term Eff Med Implants. 2018;28(3):181-185. doi: 10.1615/JLongTermEffMedImplants.2018027914.

PMID:
30806274
17.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338
18.

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

Johnson DB, Bao R, Ancell KK, Daniels AB, Wallace D, Sosman JA, Luke JJ.

J Natl Compr Canc Netw. 2019 Feb;17(2):114-117. doi: 10.6004/jnccn.2018.7070.

PMID:
30787124
19.

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.

Gupta R, Bugide S, Wang B, Green MR, Johnson DB, Wajapeyee N.

Proc Natl Acad Sci U S A. 2019 Feb 19. pii: 201821889. doi: 10.1073/pnas.1821889116. [Epub ahead of print]

PMID:
30782837
20.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM.

Pigment Cell Melanoma Res. 2019 Feb 15. doi: 10.1111/pcmr.12775. [Epub ahead of print]

PMID:
30767428
21.

Targeting tissue factor in advanced solid tumours.

Davis EJ, Johnson DB.

Lancet Oncol. 2019 Mar;20(3):318-319. doi: 10.1016/S1470-2045(18)30912-4. Epub 2019 Feb 8. No abstract available.

PMID:
30745091
22.

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.

Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Erratum in: Cardiovasc Res. 2019 Apr 15;115(5):868.

PMID:
30715219
23.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

PMID:
30690710
24.

Isolated Treatment of a Comminuted Capitate Fracture: A Case Report.

Johnson DB Jr, Triplet JJ, Bernhardt L, Buchan DR, Iorio T.

JBJS Case Connect. 2019 Jan-Mar;9(1):e6. doi: 10.2106/JBJS.CC.18.00166.

PMID:
30676344
25.

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.

Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, Ascano M, Kelley M, Johnson DB, Balko JM, Wilson JT.

Nat Nanotechnol. 2019 Mar;14(3):269-278. doi: 10.1038/s41565-018-0342-5. Epub 2019 Jan 21.

PMID:
30664751
26.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

27.

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.

PMID:
30630828
28.

Nontraumatic Compartment Syndrome in a Patient with Protein S Deficiency: A Case Report.

Pentz K, Triplet JJ, Johnson DB, Umbel B, Baker TE.

JBJS Case Connect. 2018 Oct-Dec;8(4):e82. doi: 10.2106/JBJS.CC.18.00055.

PMID:
30601765
29.

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Johnson DB, Balko JM.

Clin Cancer Res. 2019 Mar 1;25(5):1452-1454. doi: 10.1158/1078-0432.CCR-18-3858. Epub 2018 Dec 26.

PMID:
30587548
30.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

31.

Acidithiobacillus ferrooxidans.

Quatrini R, Johnson DB.

Trends Microbiol. 2019 Mar;27(3):282-283. doi: 10.1016/j.tim.2018.11.009. Epub 2018 Dec 15.

PMID:
30563727
32.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

PMID:
30546965
33.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.

PMID:
30521084
34.

School Lunch Entrées Before and After Implementation of the Healthy, Hunger-Free Kids Act of 2010.

Mozer L, Johnson DB, Podrabsky M, Rocha A.

J Acad Nutr Diet. 2019 Mar;119(3):490-499. doi: 10.1016/j.jand.2018.09.009. Epub 2018 Nov 23.

PMID:
30473488
35.

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Axelrod ML, Cook RS, Johnson DB, Balko JM.

Clin Cancer Res. 2019 Apr 15;25(8):2392-2402. doi: 10.1158/1078-0432.CCR-18-3200. Epub 2018 Nov 21. Review.

PMID:
30463850
36.

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ.

Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12.

PMID:
30442497
37.

Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.

Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM.

Cancer Immunol Res. 2019 Jan;7(1):86-99. doi: 10.1158/2326-6066.CIR-17-0692. Epub 2018 Nov 9.

PMID:
30413431
38.

Immune Checkpoint Inhibitor-Associated Myositis.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y.

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898. No abstract available.

PMID:
30359135
39.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
40.

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.

Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC.

Diabetes Care. 2018 Dec;41(12):e150-e151. doi: 10.2337/dc18-1465. Epub 2018 Oct 10. No abstract available.

PMID:
30305348
41.

Biomechanical Assessment of Torsional Stiffness in a Supracondylar Humerus Fracture Model.

Wallace M, Johnson DB, Pierce W, Iobst C, Riccio A, Wimberly RL.

J Pediatr Orthop. 2019 Mar;39(3):e210-e215. doi: 10.1097/BPO.0000000000001270.

PMID:
30300279
42.

Immune Checkpoint Inhibitor Toxicity in 2018.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995. No abstract available.

PMID:
30286224
43.

Identification of trehalose as a compatible solute in different species of acidophilic bacteria.

Galleguillos PA, Grail BM, Hallberg KB, Demergasso CS, Johnson DB.

J Microbiol. 2018 Oct;56(10):727-733. doi: 10.1007/s12275-018-8176-2. Epub 2018 Sep 28.

PMID:
30267316
44.

An Assessment of Perceived Barriers to Farmers' Market Access.

Ritter G, Walkinshaw LP, Quinn EL, Ickes S, Johnson DB.

J Nutr Educ Behav. 2019 Jan;51(1):48-56. doi: 10.1016/j.jneb.2018.07.020. Epub 2018 Sep 21.

PMID:
30249521
45.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

PMID:
30242316
46.
47.

Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB.

Lancet. 2018 Aug 4;392(10145):384-385. doi: 10.1016/S0140-6736(18)31556-3. No abstract available.

PMID:
30102170
48.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK.

JCI Insight. 2018 Jul 26;3(14). pii: 120422. doi: 10.1172/jci.insight.120422. eCollection 2018 Jul 26.

49.

Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition.

Johnson DB, Dahlman KB.

Clin Cancer Res. 2018 Dec 15;24(24):6107-6109. doi: 10.1158/1078-0432.CCR-18-1795. Epub 2018 Jul 24.

PMID:
30042206
50.

Biomarkers for immune therapy in melanoma.

Johnson DB, Chon J, Johnson MR, Balko JM.

Semin Cutan Med Surg. 2018 Jun;37(2):120-126. doi: 10.12788/j.sder.2018.019.

PMID:
30040089

Supplemental Content

Loading ...
Support Center